TERNTerns Pharmaceuticals Inc

Truist called Viking a “differentiated player” in the crowded obesity market, highlighting its flagship VK2735 candidate and dual oral-plus-injectable GLP-1 strategy.

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the successful completion of the acquisition of Terns Pharmaceuticals, Inc. (Terns) (Nasdaq: TERN). The Terns acquisition reflects Mercks continued focus on sciencedriven, valueenhancing business development...

Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Get Free Report) has earned a consensus recommendation of "Hold" from the fifteen analysts that are covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, ten have assigned a hold recommen...

Merck tops Q1 estimates as Keytruda drives growth and lifts 2026 EPS outlook despite acquisition charge. Sales view tightened.

Pictet Asset Management Holding SA lifted its position in shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Free Report) by 42.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,577...

Oppenheimer restated a "market perform" rating and set a $58.00 target price on shares of Terns Pharmaceuticals in a research report on Monday...

Merck heads into Q1 with strong Keytruda demand but rising pressure from generics, vaccines slump, and deal costs persist. Can it retain growth momentum?

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (HSR), in...

Merck stock up 11% YTD as Keytruda growth, pipeline gains and M&A lift outlook, but patent risks, Gardasil slump and generics weigh on near-term upside.